World Health Assembly (WHA)
Access to Medicines: Experiences with Compulsory Licenses and Government Use – The case of Hepatitis C
This South Centre research paper discusses first, the limitations of the current research and development (R&D) model and its implications for access to medicines. Second, it considers the tension between intellectual property rights applied to medicines and States’ observance of the fundamental right to health. Third, it examines the case of access to medicines for the treatment of Hepatitis C, illustrating the barriers to access created by intellectual property and the high prices normally associated with its exercise. Fourth, it presents the background, main aspects and obstacles to the achievement of the objectives of the Doha Declaration on the TRIPS Agreement and Public Health (2001). To conclude, this paper examines the experiences of compulsory licensing and government use of patents in Latin America (particularly in Ecuador, Peru and Colombia).
South Centre Statement for the Informal Consultation on the Roadmap on Access to Medicines
The draft roadmap is an important work in progress that needs to be further detailed with clear deliverables and timelines. The roadmap will need to ensure complementarity of its work and the implementation of the Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property (GSPOA).
This update provides a snapshot of the publications and social media activities of the South Centre during the month of July 2018.
Title: Side Event to the 71st World Health Assembly, on Access to Medicines: Overcoming Obstacles created by monopolies – Essential to UHC and the 2030 Agenda
Date: 25 May 2018
Venue: Room VIII, Palais des Nations, Geneva
Organizers: Missions of Brazil, India, Morocco, Senegal, and Thailand, with the support of the South Centre
Major Outcomes of the 71st Session of the World Health Assembly of WHO
The 71st session of the World Health Assembly (WHA) of the World Health Organization (WHO) took place from 21 to 26 May 2018 in Geneva, Switzerland. The Assembly adopted several decisions and resolutions including the adoption of the General Programme of Work (GPW) of WHO for the period 2019-2023, as well as decisions on addressing access to medicines and vaccines and their global shortage, and the recommendations of an overall programme review of the WHO Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property (GSPA-PHI). (more…)
This update provides a snapshot of the activities of the Development, Innovation and Intellectual Property Programme during the month of May 2018.
South Centre Statement at the Meeting of Ministers of Health of the Member States of the Non-Aligned Movement
The South Centre reiterates its commitment to support the Non-Aligned countries so that there is close and effective cooperation among developing countries to strengthen a global health agenda. WHO was created as an international public agency in the service of global health. Recovering and reinforcing this role should be the work of all.
Outcomes of the 142nd session of the WHO Executive Board
The 142nd session of the WHO Executive Board discussed several critical public health issues including a recommendation to the WHA to approve the General Program of Work (GPW), the adoption of important decisions relating to access to medicines and research and development and a draft resolution on the preparation of the UN High Level Meeting on Tuberculosis.
This update provides a snapshot of the activities of the Development, Innovation and Intellectual Property Programme during the month of August 2017.
State of discussion on AMR action, two years after the WHA Global Plan
Civil society and South Centre call for urgent actions to tackle AMR and ensure access and new innovation models